
Novo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.
The update marks the first evaluation of amycretin in people with type 2 diabetes.

Novo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.
The update marks the first evaluation of amycretin in people with type 2 diabetes.